Amgen Stock Dives
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Since its establishment in 1990, the ABE program has now reached over 1 million students across 16 countries, helping to ...
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024 ...
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback